Mario Sznol
Yale New Haven Hospital
3 papers in the Anchorcite directory, published between 2012 and 2015, cited 25,421 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Immunotherapy and Immune Responses · 2 papers
- Cutaneous Melanoma Detection and Management · 2 papers
- T-cell and B-cell Immunology · 1 paper
- Melanoma and MAPK Pathways · 1 paper
Frequent co-authors
- Frank Stephen Hodi · 2 papers
- Alan J. Korman · 2 papers
- Ashok Kumar Gupta · 2 papers
- Jon M. Wigginton · 2 papers
- Margaret K. Callahan · 2 papers
- Michael Andrew Postow · 2 papers
- Christine E. Horak · 2 papers
- Jedd D. Wolchok · 2 papers
Papers
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine · 2012 · 12,793 citations
BACKGROUND: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. METHODS: We enrolled patients with advanced melanoma,…
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations
BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab…
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2013 · 4,287 citations
BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis…
Metadata from OpenAlex (CC0).